The short version of trans-3-hexenoyl fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-10 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
== Patents == This is a highly competitive area and a number of people claim patents in the field, most notably Alere (formerly Inverness Medical Innovations, now owned by Abbott) who own patents originally filed by Unipath. The US 6,485,982 patent, that has been litigated, expired in 2019. A number of other companies also hold patents in this arena. A group of competitors are challenging the validity of the patents. The original patent is apparently from 1988.
DABA derivatives A novel family of zinc-targeting diaminobenzoic acid (DABA) compounds were rationally designed bearing natural and unnatural aminoacid moieties, with micromolar potency for IRAP (compound 6, IC50 = 2.1 μM) and moderate selectivity over ERAP1 and ERAP2. Aryl sulfonamides In 2014, Vanga et al recognized the ability of aryl sulfonamides to inhibit IRAP after screening a library of 10,500 drug-like compounds. After further optimization, compound 7 was developed displaying micromolar affinity towards IRAP (IC50 = 0.8 μM).
=== In insects === Insect PαAMs are responsive to O2 concentrations and depends upon Cu2+. Simpson et al 2015 finds insect PαAMs to respond to hypoxia by regulating the activity of several peptide hormones. They find PαAM to probably be an important part of neuroendocrine responses to hypoxia.
Deeper water is preferable, to avoid issues related with dynamic loading. Ice along shorelines and above shoals is prone to fracturing. Avoid areas where there are strong water currents, or next to the mouth of small rivers and creeks. The temperature at the ice-water interface being 0 °C (32 °F), flow of water at a slightly higher temperature will thermally erode that interface, thereby reducing the ice thickness. Consider the effects of water level changes, for instance upstream of a water body regulated by dams. A review of historical ice conditions, using local knowledge and satellite imagery, can help decipher recurrent problematic areas, such as ice ridging. Before first access to the ice, the following factors need to be considered:
Sources: en.wikipedia.org
==== Anti-inflammatory treatments ==== Topical corticosteroids are effective in short-term treatment of seborrhoeic dermatitis and are as effective or more effective than antifungal treatment with azoles. These are sometimes used for a few weeks at a time. There is also evidence for the effectiveness of topical calcineurin inhibitors like tacrolimus and pimecrolimus as well as lithium salt therapy. Calcineurin inhibitors were also effective in reducing the growth of Malassezia, offering two routes by which they may treat seborrhoeic dermatitis. Medications such as calcineurin inhibitors are not often used in individuals with seborrhoeic dermatitis who are immunocompromised because they cause further immune suppression. Oral immunosuppressive treatment, such as with prednisone, has been used in short courses for seborrhoeic dermatitis, as a last resort due to its potential side effects.
=== Welsh === Llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogoch, a railway station on the island of Anglesey in Wales, is the longest place name in the Welsh language. At 51 letters in the Welsh alphabet (the digraphs ll and ch are each collated as single letters) the name can be translated as "St Mary's church in the hollow of the white hazel near to the rapid whirlpool and the church of St Tysilio of the red cave". However, it was artificially contrived in the 1860s as a publicity stunt, to give the station the longest name of any railway station in the United Kingdom. Long words are comparatively rare in Welsh. Candidates for long words other than proper nouns include the following (the digraph dd is also treated as a single letter, as is ng in many instances including in the last word below):
=== Creation === The concretisation of the idea of a new museum entirely dedicated to archaeology in the canton took 22 years, from the first motion before the Grand Council of Neuchâtel to the inauguration of the museum in 2001. It also took the people of the Canton of Neuchâtel approval, the projects was accepted with 66% of the votes on June 9, 1996.
=== Reagent for organic chemistry === (−)-Cytisine extracted from Laburnum anagyroides seeds was used as a starting material for the preparation of "(+)-sparteine surrogate", for the preparation of enantiomerically enriched lithium anions of opposite stereochemistry to those anions obtained from sparteine.
Monster Energy is the primary sponsor for Yamaha Motor Racing in MotoGP since 2019 and also sponsors riders such as Valentino Rossi, Franco Morbidelli, and Francesco Bagnaia. The firm has also been the title sponsor of the Catalan motorcycle Grand Prix since 2014, and the British motorcycle Grand Prix since 2021. The brand has been the main sponsor of the Speedway Grand Prix and Speedway World Cup since 2012, and also supports several riders. Monster has sponsored motocross riders such as Jeremy McGrath, Chad Reed, Ryan Villopoto, Nate Adams, Taka Higashino and Ricky Carmichael. The brand sponsors the Kawasaki, and Yamaha motocross factory teams. In 2016, the firm aided the return of factory Yamaha to the United States as the title sponsor of the team, officially named Monster Energy/360fly/Chaparral/Yamaha Factory Racing. During this time, Monster Energy served as a title sponsor for the Star Racing Yamaha team, which also took over the 450 program from Factory Yamaha in 2021. They have gone on to win the 2021 AMA Pro Motocross Championship with Dylan Ferrandis, and the 2022 AMA Supercross and AMA Pro Motocross Championships with Eli Tomac. The brand is also the main sponsor of the Honda and Hero factory teams in the FIM Cross-Country Rallies World Championship and later the World Rally-Raid Championship since 2016 and 2023 respectively.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.